{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:35:11Z","timestamp":1780925711739,"version":"3.54.1"},"reference-count":64,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: The standard surgical treatment of muscle-invasive bladder cancer (MIBC) comprises neoadjuvant systemic therapy followed by radical cystectomy (RC). However, a notable number of patients achieve a favorable response to neoadjuvant systemic therapy, a finding associated with improved outcomes, and questioning the necessity of RC in this subset of patients. The objective of this review is to summarize the available evidence regarding the feasibility, efficacy and toxicity of bladder-preserving chemoradiotherapy (CRT) following clinical response (CR) to neoadjuvant systemic therapy in patients with MIBC. Methods: A literature search was performed using the PubMed database to identify studies evaluating the use of CRT for bladder preservation in MIBC patients with CR following neoadjuvant therapy. Results: Clinical complete response (cCR) rates to neoadjuvant systemic treatment ranged from 31% to 87.5%, with subsequent CRT enabling 50\u201397% of responders to retain their bladder. Long-term outcomes were favorable for cCR patients, with 3- to 5-year overall survival (OS) ranging from 65% to 89%, disease-free survival (DFS) of 64\u201386%, and bladder-intact survival up to 80%. Achievement of cCR, T2 tumor stage, absence of concomitant carcinoma in situ or hydronephrosis, and complete transurethral resection of the bladder tumor (TURBT) were prognostic factors for improved oncologic outcomes. Treatment-related toxicity was generally acceptable, concerning mainly hematological and gastrointestinal events, while severe late toxicity was uncommon. Conclusions: Bladder-preserving CRT is a promising, effective, and well-tolerated option for MIBC patients achieving CR to neoadjuvant systemic therapy. While further prospective validation and longer follow-up are required before it can universally replace radical cystectomy in this subset of patients, advances in neoadjuvant treatments, imaging and molecular biomarkers may improve response assessment and patient selection for bladder preservation.<\/jats:p>","DOI":"10.3390\/cancers18060961","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T14:30:32Z","timestamp":1773671432000},"page":"961","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bladder Preservation with Concurrent Chemoradiotherapy Following Complete Response to Induction Systemic Therapy in Patients with Muscle-Invasive Bladder Cancer: A Review of the Existing Literature"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8770-7142","authenticated-orcid":false,"given":"Georgios Nikiforos","family":"Ntoumas","sequence":"first","affiliation":[{"name":"Department of Clinical Radiation Oncology, Medical School, ATTIKON University Hospital, National and Kapodistrian University of Athens, 124 62 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andromachi","family":"Kougioumtzopoulou","sequence":"additional","affiliation":[{"name":"Department of Clinical Radiation Oncology, Medical School, ATTIKON University Hospital, National and Kapodistrian University of Athens, 124 62 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-2395","authenticated-orcid":false,"given":"Dimitra","family":"Desse","sequence":"additional","affiliation":[{"name":"Department of Clinical Radiation Oncology, Medical School, ATTIKON University Hospital, National and Kapodistrian University of Athens, 124 62 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalambos","family":"Fragkoulis","sequence":"additional","affiliation":[{"name":"Department of Urology, General Hospital of Athens \u201cG. Gennimatas\u201d, 115 27 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Papadopoulos","sequence":"additional","affiliation":[{"name":"Department of Urology, General Hospital of Athens \u201cG. Gennimatas\u201d, 115 27 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efthymios","family":"Kostouros","sequence":"additional","affiliation":[{"name":"3rd Department of Internal Medicine, General Hospital of Athens \u201cG. Gennimatas\u201d, 115 27 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Michaletou","sequence":"additional","affiliation":[{"name":"Department of Clinical Radiation Oncology, Medical School, ATTIKON University Hospital, National and Kapodistrian University of Athens, 124 62 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2082-7323","authenticated-orcid":false,"given":"Vassileios","family":"Kouloulias","sequence":"additional","affiliation":[{"name":"Department of Clinical Radiation Oncology, Medical School, ATTIKON University Hospital, National and Kapodistrian University of Athens, 124 62 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Zygogianni","sequence":"additional","affiliation":[{"name":"Department of Clinical Radiation Oncology, Medical School, ATTIKON University Hospital, National and Kapodistrian University of Athens, 124 62 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6354-9805","authenticated-orcid":false,"given":"Ioannis","family":"Georgakopoulos","sequence":"additional","affiliation":[{"name":"Radiotherapy Unit, 1st Department of Radiology, Medical School, Aretaieion University Hospital, National and Kapodistrian University of Athens, 115 28 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Filho, A.M., Briganti, A., Jemal, A., and Bray, F. (2025). Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur. Urol., in press.","DOI":"10.1016\/j.eururo.2025.12.011"},{"key":"ref_2","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA A Cancer J. Clin."},{"key":"ref_3","first-page":"404","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA A Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.semradonc.2022.10.007","article-title":"Myths About Bladder Preservation in Muscle-Invasive Bladder Cancer","volume":"33","author":"Elumalai","year":"2023","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0022-5347(05)66440-3","article-title":"Cystectomy for Bladder Cancer: A Contemporary Series","volume":"165","author":"Dalbagni","year":"2001","journal-title":"J. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s00345-006-0061-7","article-title":"Radical cystectomy for invasive bladder cancer: Long-term results of a standard procedure","volume":"24","author":"Stein","year":"2006","journal-title":"World J. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients","volume":"19","author":"Stein","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.juro.2009.05.032","article-title":"Complications and Mortality After Radical Cystectomy for Bladder Transitional Cell Cancer","volume":"182","author":"Novara","year":"2009","journal-title":"J. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"110038","DOI":"10.1016\/j.radonc.2023.110038","article-title":"Quality of Life after Definitive Treatment for Bladder Cancer: A Systematic Review and Meta-Analysis","volume":"190","author":"Francolini","year":"2024","journal-title":"Radiother. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, the Australian Bladder Cancer Study Group, the National Cancer Institute of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group, and Club Urologico Espanol de Tratamiento Oncologico Group (2011). International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial. J. Clin. Oncol., 29, 2171\u20132177.","DOI":"10.1200\/JCO.2010.32.3139"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"key":"ref_13","first-page":"5","article-title":"Systematic Review and Meta-Analysis of Cisplatin Based Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer","volume":"8","author":"Benkhadra","year":"2021","journal-title":"Bl. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Nikulainen, I., Salminen, A.P., H\u00f6german, M., Seikkula, H., Bostr\u00f6m, P.J., and The Finnish National Cystectomy Database Research Group (2025). Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: A Nationwide Analysis of Eligibility, Utilization, and Outcomes. Cancers, 17.","DOI":"10.3390\/cancers17030505"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.21.02051","article-title":"Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial","volume":"40","author":"Pfister","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Lee, H.W., Kwon, W.-A., Nguyen, L.N.T., Phan, D.T.T., and Seo, H.K. (2023). Approaches to Clinical Complete Response after Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Possibilities and Limitations. Cancers, 15.","DOI":"10.3390\/cancers15041323"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S1763","DOI":"10.1016\/j.annonc.2025.09.124","article-title":"LBA2 Perioperative (Periop) Enfortumab Vedotin (EV) plus Pembrolizumab (Pembro) in Participants (Pts) with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin-Ineligible: The Phase III KEYNOTE-905 Study","volume":"36","author":"Vulsteke","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/bju.15434","article-title":"Optimal Pathological Response after Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer: Results from a Global, Multicentre Collaboration","volume":"128","author":"Ravi","year":"2021","journal-title":"BJU Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1200\/JCO.1996.14.1.119","article-title":"Neoadjuvant Combined Modality Program with Selective Organ Preservation for Invasive Bladder Cancer: Results of Radiation Therapy Oncology Group Phase II Trial 8802","volume":"14","author":"Tester","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0022-5347(17)36199-2","article-title":"Methotrexate, Vinblastine, Doxorubicin and Cisplatin Followed by Radiotherapy or Surgery for Muscle Invasive Bladder Cancer: The University of Chicago Experience","volume":"149","author":"Vogelzang","year":"1993","journal-title":"J. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/0360-3016(93)90305-F","article-title":"Sequential transurethral surgery, multiple drug chemotherapy and radiation therapy for invasive bladder carcinoma: Initial report","volume":"25","author":"Kragelj","year":"1993","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1200\/JCO.1993.11.11.2150","article-title":"Combined Radiation and Chemotherapy for Invasive Transitional-Cell Carcinoma of the Bladder: A Prospective Study","volume":"11","author":"Housset","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0090-4295(99)80262-3","article-title":"Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: A five-year follow-up","volume":"46","author":"Given","year":"1995","journal-title":"Urology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8<1464::AID-CNCR14>3.0.CO;2-3","article-title":"Combined Treatment of Invasive Bladder Carcinoma with Transurethral Resection, Induction Chemotherapy, and Radical Radiotherapy plus Concomitant Protracted Infusion of Cisplatin and 5-fluorouracil","volume":"80","author":"Danesi","year":"1997","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.1998.16.11.3576","article-title":"Phase III Trial of Neoadjuvant Chemotherapy in Patients with Invasive Bladder Cancer Treated with Selective Bladder Preservation by Combined Radiation Therapy and Chemotherapy: Initial Results of Radiation Therapy Oncology Group 89-03","volume":"16","author":"Shipley","year":"1998","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1200\/JCO.1997.15.3.1022","article-title":"Bladder Preservation by Combined Modality Therapy for Invasive Bladder Cancer","volume":"15","author":"Kachnic","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_28","first-page":"59","article-title":"Continuous Chemoradiation Following Complete Response to Neo-Adjuvant Chemotherapy Provides Improved Outcomes in Muscle Invasive Urothelial Carcinoma","volume":"5","author":"Araujo","year":"2015","journal-title":"J. Solid Tumors"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clgc.2018.09.021","article-title":"Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer","volume":"17","author":"Jiang","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0360-3016(00)00444-2","article-title":"Chemoradiotherapy for Muscle Invading Bladder Carcinoma. Final Report of a Single Institutional Organ-Sparing Program","volume":"47","author":"Arias","year":"2000","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.urology.2004.04.088","article-title":"Clinical Outcome in Patients with Locally Advanced Bladder Carcinoma Treated with Conservative Multimodality Therapy","volume":"64","author":"George","year":"2004","journal-title":"Urology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s12094-006-0154-1","article-title":"Conservative Treatment with Transurethral Resection, Neoadjuvant Chemotherapy Followed by Radiochemotherapy in Stage T2-3 Transitional Bladder Cancer","volume":"8","author":"Cobo","year":"2006","journal-title":"Clin. Transl. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/cncr.23137","article-title":"Bladder-sparing, Combined-modality Approach for Muscle-invasive Bladder Cancer","volume":"112","author":"Autorino","year":"2008","journal-title":"Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ijrobp.2008.11.030","article-title":"Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer","volume":"75","author":"Lin","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_35","first-page":"14","article-title":"Combined modality treatment with bladder preservation for muscle invasive bladder cancer","volume":"28","author":"Sabaa","year":"2010","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.4143\/crt.2020.1356","article-title":"Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study","volume":"53","author":"Shi","year":"2021","journal-title":"Cancer Res. Treat."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-0041-1723076","article-title":"Bladder Preservation with Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for the Treatment of Muscle-invasive Carcinoma of the Bladder: A Single-Center Experience","volume":"9","author":"Agrawal","year":"2020","journal-title":"South Asian J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ajur.2021.06.006","article-title":"A Phase II Study of Neoadjuvant Chemotherapy Followed by Organ Preservation in Patients with Muscle-Invasive Bladder Cancer","volume":"9","author":"Dracham","year":"2022","journal-title":"Asian J. Urol."},{"key":"ref_39","first-page":"1","article-title":"Bladder Preservation by Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer","volume":"27","author":"Elsayed","year":"2023","journal-title":"Contemp. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"893","DOI":"10.4143\/crt.2024.015","article-title":"Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies","volume":"56","author":"Cho","year":"2024","journal-title":"Cancer Res. Treat."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2025.43.5_suppl.786","article-title":"Long-Term Results of a Phase 2 Study of Neoadjuvant Chemotherapy Combined with Tislelizumab Followed by Radiotherapy for Bladder-Preserving Treatment in Selected High-Risk\/Locally Advanced Muscle Invasive Urothelial Bladder Cancer (HOPE-02)","volume":"43","author":"Wen","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1200\/JCO.1991.9.9.1533","article-title":"Prognostic Factors in Invasive Bladder Carcinoma in a Prospective Trial of Preoperative Adjuvant Chemotherapy and Radiotherapy","volume":"9","author":"Fung","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-Term Outcomes of Selective Bladder Preservation by Combined-Modality Therapy for Invasive Bladder Cancer: The MGH Experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_44","unstructured":"(2026, January 20). EAU Guidelines Office, Arnhem, The Netherlands. Available online: http:\/\/uroweb.org\/guidelines\/compilations-of-all-guidelines\/."},{"key":"ref_45","unstructured":"(2026, January 20). NCCN Clinical Practice Guidelines in Oncology, Bladder Cancer Version 3.2025. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1590\/s1677-5538.ibju.2020.99.01","article-title":"Bladder preservation in muscle-invasive bladder cancer: A comprehensive review","volume":"46","author":"Hamad","year":"2020","journal-title":"Int. Braz. J. Urol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical Cystectomy versus Trimodality Therapy for Muscle-Invasive Bladder Cancer: A Multi-Institutional Propensity Score Matched and Weighted Analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijrobp.2023.07.027","article-title":"Disease-Free Survival of Patients With Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder-Preserving Therapy: A Nationwide Study","volume":"118","author":"Meijer","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eururo.2025.03.017","article-title":"Bladder Preservation Strategies in Muscle-Invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group","volume":"89","author":"Gupta","year":"2026","journal-title":"Eur. Urol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.euf.2025.11.002","article-title":"Bladder Preservation After Neoadjuvant Therapy for Muscle-invasive Bladder Cancer in the Current Era: Myth and Reality","volume":"12","author":"Crupi","year":"2026","journal-title":"Eur. Urol. Focus"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.urology.2017.09.003","article-title":"Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-Invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy","volume":"111","author":"Robins","year":"2018","journal-title":"Urology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/21681805.2021.1981996","article-title":"Control Computerized Tomography in Neoadjuvant Chemotherapy for Muscle Invasive Urinary Bladder Cancer Has No Value for Treatment Decisions and Low Correlation with Nodal Status","volume":"55","author":"Tenninge","year":"2021","journal-title":"Scand. J. Urol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1007\/s00261-021-02963-7","article-title":"Diagnostic performance of contrast-enhanced dynamic and diffusion-weighted MR imaging in the assessment of tumor response to neoadjuvant therapy in muscle-invasive bladder cancer","volume":"46","author":"Ahmed","year":"2021","journal-title":"Abdom. Radiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00261-021-03365-5","article-title":"Vesical Imaging-Reporting and Data System (VI-RADS) for Assessment of Response to Systemic Therapy for Bladder Cancer: Preliminary Report","volume":"47","author":"Pecoraro","year":"2022","journal-title":"Abdom. Radiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.euo.2020.06.004","article-title":"The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-Invasive Bladder Cancer","volume":"4","author":"Bandini","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e233020","DOI":"10.1148\/radiol.233020","article-title":"Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-Invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI","volume":"313","author":"Brembilla","year":"2024","journal-title":"Radiology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/RLU.0000000000004639","article-title":"Predictive Value of 18F-FDG PET\/CT for Assessment of Tumor Response to Neoadjuvant Chemotherapy in Bladder Cancer","volume":"48","author":"Ko","year":"2023","journal-title":"Clin. Nucl. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"TPS4617","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4617","article-title":"EA8185: Phase 2 study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node-positive urothelial carcinoma (INSPIRE), an ECOG-ACRIN\/NRG collaboration","volume":"40","author":"Joshi","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.juro.2018.05.078","article-title":"Conservative Management Following Complete Clinical Response to Neoadjuvant Chemotherapy of Muscle Invasive Bladder Cancer: Contemporary Outcomes of a Multi-Institutional Cohort Study","volume":"200","author":"Mazza","year":"2018","journal-title":"J. Urol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1200\/JCO-24-01214","article-title":"Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1)","volume":"43","author":"Geynisman","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1200\/JCO.2025.43.5_suppl.815","article-title":"A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2)","volume":"43","author":"Ghatalia","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1200\/JCO.2025.43.16_suppl.4518","article-title":"First results of SURE-02: A phase 2 study of neoadjuvant sacituzumab govitecan (SG) plus pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant pembro, in patients with muscle-invasive bladder cancer (MIBC)","volume":"43","author":"Necchi","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.euo.2025.03.005","article-title":"Challenges in Defining Clinical Complete Response to Systemic Therapy in Muscle-invasive Bladder Cancer: Insights from the EORTC STARBURST Project","volume":"8","author":"Grisay","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"ref_64","first-page":"TPS890","article-title":"NEO-BLAST: Neoadjuvant therapy for bladder cancer followed by active surveillance vs treatment","volume":"43","author":"Eigl","year":"2025","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/6\/961\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T14:41:18Z","timestamp":1773672078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/6\/961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":64,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["cancers18060961"],"URL":"https:\/\/doi.org\/10.3390\/cancers18060961","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]}}}